{"tm":1686889061,"s":"BMY","news":[{"t":"U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS\u00ae (mavacamten) Label","dt":"Jun-15-23 08:23PM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/u-food-drug-administration-approves-002300597.html"},{"t":"Bristol Myers Squibb Announces Dividend","dt":"Jun-14-23 04:16PM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-announces-dividend-201600105.html"},{"t":"15 Most Profitable Drugs In The World","dt":"06:04AM","a":"Insider Monkey","u":"https:\/\/finance.yahoo.com\/news\/15-most-profitable-drugs-world-100455774.html"},{"t":"Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts","dt":"Jun-08-23 04:16PM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-receives-u-201600649.html"},{"t":"Here's Why Bristol-Myers Squibb (NYSE:BMY) Has Caught The Eye Of Investors","dt":"07:00AM","a":"Simply Wall St.","u":"https:\/\/finance.yahoo.com\/news\/heres-why-bristol-myers-squibb-110035372.html"},{"t":"Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer","dt":"Jun-04-23 08:00AM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/four-outcomes-phase-3-checkmate-120000872.html"},{"t":"The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree","dt":"01:17PM","a":"Investor's Business Daily","u":"https:\/\/finance.yahoo.com\/m\/a801739e-ae01-39b0-9c29-dc4fb42d512d\/the-biotech-buying-bonanza%3A.html"},{"t":"Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know","dt":"Jun-01-23 05:45PM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-bmy-gains-214518582.html"},{"t":"Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval &amp; More","dt":"11:35AM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/biotech-stock-roundup-mrtx-falls-153500023.html"},{"t":"Bristol Myers Squibb to Participate in Upcoming Investor Conferences","dt":"06:59AM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-participate-upcoming-105900777.html"},{"t":"Bristol Myers Squibb to Hold R&amp;D Day on September 14","dt":"06:59AM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-hold-r-105900227.html"},{"t":"U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibbs Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer","dt":"06:59AM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/u-food-drug-administration-accepts-105900511.html"},{"t":"Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation","dt":"May-26-23 12:32PM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-bmy-thrombosis-drug-163200390.html"},{"t":"Bristol Myers Squibbs Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023","dt":"May-25-23 05:05PM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-breyanzi-lisocabtagene-210500753.html"},{"t":"Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation","dt":"06:59AM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/milvexian-granted-u-fda-fast-105900364.html"},{"t":"Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results","dt":"May-23-23 12:30PM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-bmy-reports-pulmonary-163000801.html"},{"t":"1 Dirt Cheap Dividend Stock to Buy in May","dt":"May-19-23 10:07AM","a":"Motley Fool","u":"https:\/\/finance.yahoo.com\/m\/31f5261e-126a-3762-b47d-c0539cff5c90\/1-dirt-cheap-dividend-stock.html"},{"t":"Is Bristol-Myers Squibb Stock a Buy Now?","dt":"May-11-23 09:17AM","a":"Motley Fool","u":"https:\/\/finance.yahoo.com\/m\/fc1c5a0e-1df6-346f-8511-6c96bac8dc0f\/is-bristol-myers-squibb-stock.html"},{"t":"3 Things About Bristol-Myers Squibb That Smart Investors Know","dt":"08:45AM","a":"Motley Fool","u":"https:\/\/finance.yahoo.com\/m\/50130f10-bd1d-3511-92ac-2fb60c9a2198\/3-things-about-bristol-myers.html"},{"t":"Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates","dt":"May-05-23 12:27PM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/prothena-prta-q1-earnings-revenues-162704357.html"},{"t":"Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Is Well Worth Watching","dt":"07:00AM","a":"Simply Wall St.","u":"https:\/\/finance.yahoo.com\/news\/heres-why-think-bristol-myers-110027888.html"},{"t":"Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy","dt":"06:59AM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-receives-european-105900353.html"},{"t":"15 Best Income Stocks to Buy According to Analysts","dt":"09:01AM","a":"Insider Monkey","u":"https:\/\/finance.yahoo.com\/news\/15-best-income-stocks-buy-130112119.html"},{"t":"Bristol Myers Squibbs TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate","dt":"06:59AM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-transcend-fl-105900989.html"},{"t":"Q1 2023 Bristol-Myers Squibb Co Earnings Call","dt":"Apr-28-23 12:26AM","a":"Thomson Reuters StreetEvents","u":"https:\/\/finance.yahoo.com\/news\/q1-2023-bristol-myers-squibb-042637576.html"},{"t":"Analyst Report: Bristol-Myers Squibb Company","dt":"10:40AM","a":"Morningstar Research","u":"https:\/\/finance.yahoo.com\/m\/0a08cb2d-ff32-34f3-a951-a70cc52404e0\/analyst-report%3A-bristol-myers.html"},{"t":"Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates","dt":"08:15AM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-bmy-surpasses-121512354.html"},{"t":"Bristol Myers posts lower Q1 sales as Revlimid falls","dt":"06:59AM","a":"Reuters","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-posts-lower-q1-105900000.html"},{"t":"Bristol Myers CEO Caforio to step down","dt":"04:59PM","a":"Reuters","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-ceo-caforio-steps-205947704.html"},{"t":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS\u00ae (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)","dt":"02:42PM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-receives-positive-184200509.html"},{"t":"Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production","dt":"06:59AM","a":"Business Wire","u":"https:\/\/finance.yahoo.com\/news\/bristol-myers-squibb-strengthens-cell-105900591.html"},{"t":"Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic &amp; Altria Group","dt":"Apr-25-23 01:47PM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/q1-earnings-scorecard-fresh-analyst-174705220.html"},{"t":"Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to Decline","dt":"10:00AM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/earnings-preview-vertex-pharmaceuticals-vrtx-140002665.html"}]}